BACKGROUND Information about the long-term follow-up and safety of granulocyte colony-stimulating factor administration to healthy donors is limited. The aims of this study were to analyze the side effects of granulocyte colony-stimulating factor administration in donors included in a Spanish Registry of hematopoietic stem cell donors and to determine the long-term outcome of these donors. DE...

1 Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258: 1123–1142. 2 Kitamura T, Tanaka N, Watanabe J, et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190: 875–880. 3 Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress ...

background and objectives: during past decades hansenula polymorpha has attracted global attention for the expression of recombinant proteins due to its high growth rate, minimal nutritional porequirements and use of methanol as a low cost inducer. materials and methods: the corresponding nucleotide sequences for the expression of heterologous genes in hansenula poylmorpha were extracted and as...

INTRODUCTION The granulocyte-colony stimulating factor-producing tumor was first reported in 1977, however, anaplastic pleomorphic type carcinoma of the pancreas producing granulocyte-colony stimulating factor is still rare. CASE PRESENTATION A 63-year-old man was admitted to our hospital with body weight loss (-10 kg during months) and upper abdominal pain from 3 weeks. Abdominal computed to...

BACKGROUND Mobilization of hematopoietic stem/progenitor cells from the bone marrow to the peripheral blood by granulocyte colony-stimulating factor is the primary means to acquire stem cell grafts for hematopoietic cell transplantation. Since hematopoietic stem/progenitor cells represent a minority of all blood cells mobilized by granulocyte colony-stimulating factor, the underlying mechanisms...

Abbreviations: acute myeloid leukemia, (AML); American Society of Clinical Oncology, (ASCO); bone marrow, (BM); end stage renal disease, (ESRD); erythropoietin, (EPO); granulocyte colony-stimulating factor, (G-CSF); Granulocyte-macrophage colony-stimulating factor, (GM-CSF); hematopoietic growth factors, (HGFs); hematopoietic stem cell, (HSC); hemoglobin, (Hgb); idiopathic thrombocytopenic purp...

BACKGROUND Although mobilization of hematopoietic stem cells and hematopoietic progenitor cells can be achieved with a combination of granulocyte colony-stimulating factor and plerixafor (AMD3100), improving approaches for hematopoietic progenitor cell mobilization is clinically important. DESIGN AND METHODS Heparan sulfate proteoglycans are ubiquitous macromolecules associated with the extra...

BACKGROUND Cyclophosphamide plus thalidomide as induction for multiple myeloma patients eligible for autologous stem cell transplantation may be a limiting factor for cell mobilization. The minimum acceptable mobilized peripheral blood stem cell count to prevent deleterious effects during transplantation is 2.0×106 CD34+ cells/kg. Combining other treatments to granulocyte-colony stimulating fac...